1. Popp
AW
, BuffatH, SennC, LippunerK. Rebound-associated bone loss after non-renewal of long-term denosumab treatment offsets 10-year gains at the total hip within 12 months. J Bone Miner Res. 2016;31(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=51d4e88bf79d-47e2-a15b-134f0c57b52e. Accessed 27 September 2016.
2. Brown
JP
, FerrariS, GilchristN, Beck JensenJE, PannacciulliN, RecknorC, RouxC, SmithS, TörringO, ValterI, WagmanRB, WangAT, CummingsSR.
Discontinuation of denosumab and associated fracture incidence: analysis from FREEDOM and its extension. J Bone Miner Res. 2016;31(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=51d4e88bf79d-47e2-a15b-134f0c57b52e. Accessed 27 September 2016.